Table 6.
Adverse events up to the last study visit in patients receiving selected concomitant medications with potential for drug–drug interactions (pooled safety population)
| Patients with any AE with/without concurrent administration, n (%) | Ceftazidime–avibactam ± metronidazole (N = 2024) | Comparator (N = 2026) | ||
|---|---|---|---|---|
| With concurrent medication | Without concurrent medication | With concurrent medication | Without concurrent medication | |
| Drugs with ability to affect renal function | 143/265 (54.0) | 236/588 (40.1) | 168/284 (59.2) | 199/578 (34.4) |
| Vitamin K antagonists | 5/10 (50.0) | 386/844 (45.7) | 7/13 (53.8) | 368/848 (43.4) |
| Chloramphenicol | 4/4 (100.0) | 394/853 (46.2) | 1/2 (50.0) | 378/860 (44.0) |
| OAT1 and OAT3 inhibitors | 26/58 (44.8) | 364/793 (45.9) | 29/65 (44.6) | 346/795 (43.5) |
| Sodium picosulfate | 1/1 (100.0) | 397/856 (46.4) | 1/2 (50.0) | 380/861 (44.1) |
Percentages are based on the total number of patients in the subgroup and treatment group (N). For patients who received a selected concomitant medication, AEs were assessed after the patient had received the first dose of concomitant medication
AE adverse event